Real-World Data on the Use of Glecaprevir/Pibrentasvir in the Treatment of Hepatitis C: Is Shorter Treatment Possible?

Basit Öğe Kaydı
dc.authoridMERMUTLUOGLU, CIGDEM/0000-0003-1836-6281
dc.contributor.authorTuzun, Ahmet Yekta
dc.contributor.authorMermutluoglu, Cigdem
dc.contributor.authorCelen, Mustafa Kemal
dc.date.accessioned2025-02-22T14:08:38Z
dc.date.available2025-02-22T14:08:38Z
dc.date.issued2024
dc.departmentDicle Üniversitesien_US
dc.description.abstractObjectives: This study aimed to present real-world data on the efficacy of glecaprevir/pibrentasvir (G/P) in chronic hepatitis C (CHC) patients treated at our center. Materials and Methods: Non-cirrhotic, treatment-naive, and treatment-experienced (TN/TE) CHC patients with CHC who started G/P treatment in 2022 were included in this retrospective, cross-sectional, single-center, national study. Sustained virological response (SVR) was defined as undetectable hepatitis C virus- ribonucleic acid (HCV-RNA) for at least 12 weeks following the discontinuation of antiviral therapy. Results: Sixty patients with non-cirrhotic TN/TE CHC who started G/P were included in the study. All patients received G/P treatment for 8 weeks. The median age of the patients was 45 years (interquartile range 22-3) and 44 (73.3%) were males. The most frequently identified risk factor for CHC was substance use (n=7, 11.7%), whereas the most common comorbidities were cardiovascular disease, hypertension (n=8,13.3%), and diabetes mellitus (n=7, 11.7%). HCV genotype was evaluated in all patients. Genotype distribution: Genotype 1b was detected in 53 patients (88.3%) and genotype 1 was detected in 7 patients (11.7%). The median pretreatment HCV-RNA level of the patients was 137,000 IU/mL. HCV-RNA was evaluated in all patients at the 4 th and 8 th weeks of treatment and at the 12th th week after treatment. All patients were HCV-RNA-negative in the 1 st month of treatment. Additionally, HCV-RNA negativity continued in all patients at the end of treatment and at 12 week follow-up. No mild, moderate, or serious adverse events were observed during or after treatment. All patients were successfully treated. Conclusion: All patients extremely well tolerated the drug. The SVR response was found to be 100%. In addition, the fact that the viral load of all patients in our study was negative in the 4 th week of treatment suggested the possibility of shorter-term treatment. More studies on this subject.en_US
dc.description.sponsorshipAuthorship Contributions Surgical and Medical Practices: A.Y.T., C.M., M.K.C., Concept: C.M., Design: C.M., Data Collection or Processing: M.K.C., Analysis or Interpretation: A.Y.T., Literature Search: C.M., M.K.C., Writing: A.Y.T., C.M., M.K.C.en_US
dc.identifier.doi10.4274/vhd.galenos.2024.2024-2-1
dc.identifier.endpage40en_US
dc.identifier.issn1307-9441
dc.identifier.issn2147-2939
dc.identifier.issue2en_US
dc.identifier.scopus2-s2.0-85210937922en_US
dc.identifier.startpage36en_US
dc.identifier.urihttps://doi.org/10.4274/vhd.galenos.2024.2024-2-1
dc.identifier.urihttps://hdl.handle.net/11468/29525
dc.identifier.volume30en_US
dc.identifier.wosWOS:001309606500003en_US
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.language.isoenen_US
dc.publisherGalenos Publ Houseen_US
dc.relation.ispartofViral Hepatit Dergisi-Viral Hepatitis Journalen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.snmzKA_WOS_20250222
dc.subjectHepatitis Cen_US
dc.subjectreal-life dataen_US
dc.subjecttreatment responsesen_US
dc.titleReal-World Data on the Use of Glecaprevir/Pibrentasvir in the Treatment of Hepatitis C: Is Shorter Treatment Possible?en_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu